MAGELLAN I/ FR0011238344 /
NAV9/5/2024 | Chg.+0.0400 | Type of yield | Investment Focus | Investment company |
---|---|---|---|---|
20.5000EUR | +0.20% | reinvestment | Equity Emerging Markets | Comgest ▶ |
GlobeNewswire
8/29
Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a ...
GlobeNewswire
8/20
Navios Maritime Partners L.P. Reports Financial Results for the Second Quarter and Six Months Ended ...
GlobeNewswire
8/8
Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update
GlobeNewswire
8/5
Diamondback Energy, Inc. Announces Second Quarter 2024 Financial and Operating Results
GlobeNewswire
7/9
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Pha...
GlobeNewswire
6/27
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) For...
GlobeNewswire
6/25
Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
GlobeNewswire
5/30
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federati...
GlobeNewswire
5/14
Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire
5/14
Navios Maritime Partners L.P. Reports Financial Results for the First Quarter Ended March 31, 2024
GlobeNewswire
4/24
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase ...
GlobeNewswire
4/8
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Offi...
GlobeNewswire
4/1
Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Med...